

#### **ANALYZED BY:**

Anresco Laboratories 1375 Van Dyke Avenue, San Francisco, CA 94124 C8-0000052-LIC



#### **DISTRIBUTOR:**



#### **MANUFACTURER:**



#### **SAMPLE INFORMATION**

Sample No.: Level - Indica Hashtab -CA25HT231012d9I **Product Name:** Matrix: Concentrate (Orally Consumed Concentrate) Lot #: CA25HT231012d9I

Product-Batch Size (Units): 9326

Source UID: 1A4060300020081000003259

20 Sample Increments: Sample Weight / Increment (g): 1.69 Total Sample Weight (g): 33.8 Date Collected:

10/23/2023 **Date Received:** 10/23/2023 Date Reported: 10/26/2023

**TEST SUMMARY** 

Pass Pass **Cannabinoid Profile:** Microbiological Screen: Pesticide Residue Screen: Pass **Residual Solvent Screen:** Pass Pass Pass **Heavy Metal Screen:** Foreign Material: Pass Pass Mycotoxin Screen: Water Activity: Pass

Overall:

10/26/2023

**Cannabinoid Profile** Pass Method: MF-CHFM-15

Instrument: Liquid Chromatography Diode Array Detector (LC-DAD)

**Limit of Detection** 0.1333 mg/g Limit of Quantification 0.4000 mg/g

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
Δ8-ΤΗС	ND	ND	ND	ND	-
Δ9-ΤΗС	148.01	14.801	25.46	254.58	Pass
Δ9-ΤΗСΑ	1.92	0.192	0.33	3.30	-
THCV	0.90	0.090	0.15	1.54	-
THCVA	ND	ND	ND	ND	-
CBD	<l0q< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></l0q<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
CBDA	ND	ND	ND	ND	-
CBC	2.86	0.286	0.49	4.92	-
CBCA	<l0q< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></l0q<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
CBDV	ND	ND	ND	ND	-
CBG	5.16	0.516	0.89	8.87	-
CBGA	1.13	0.113	0.19	1.95	-
CBN	2.51	0.251	0.43	4.31	-
Total THC	149.69	14.969	25.75	257.47	-
Total CBD	<l0q< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></l0q<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
Total Cannabinoids	162.11	16.211	27.88	278.83	-
Sum of Cannabinoids	162.49	16.249	27.95	279.48	-
Serving Weight (g)	0.172				

Total THC =  $\Delta$ 9-THC + (0.877 \*  $\Delta$ 9-THCA) Total CBD = CBD + (0.877 \* CBDA)

1.72

Total Cannabinoids =  $\Sigma$  (neutral cannabinoids) + [0.877 \*  $\Sigma$  (acidic cannabinoids)]

#### **Microbiological Screen V** Pass

Package Weight (g)



10/26/2023

Analyte	Method	Findings	Status
Salmonella	AOAC 2016.01	Negative	Pass
STEC	3M MDS STEC	Negative	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124

Sample #: 1178286 Lot #: CA25HT231012d9I

Page **1** of **4** Report ID: S-2



**Pesticide Residue Screen OPASS** 

10/26/2023

MF-CHEM-13 Method:

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.02	Pass
•	0.02/0.06	ND	0.02	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos  Mevinphos				
Myclobutanil Naled	0.02/0.06 0.02/0.06	ND ND	9.0 0.5	Pass
Oxamyl	0.02/0.06	ND	0.5	Pass Pass
Paclobutrazol	0.02/0.06	ND	0.02	
			0.02	Pass
Pentachloronitrobenzene Permethrins	0.04/0.10 0.10/0.30	ND ND	20.0	Pass
				Pass
Phosmet  Discount Distortide	0.02/0.06	ND ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND ND	8.0	Pass
Prallethrin	0.04/0.10	ND ND	0.4	Pass
Propiconazole	0.02/0.06	ND ND	20.0	Pass
Propoxur	0.02/0.06	ND ND	0.02	Pass
Pyrethrins	0.15/0.50	ND ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass



LOD/LOQ (µg/g) Findings (µg/g) Limit (µg/g) Trifloxystrobin 0.02/0.06 ND 30.0 Pass

**Residual Solvent Screen** Pass

10/26/2023

MF-CHEM-32 Method:

Instrument: Gas Chromatography Mass Spectrometry (GC/MS)

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.2/0.5	ND	1	Pass
Acetone	67/200	ND	5000	Pass
Acetonitrile	67/200	ND	410	Pass
Benzene	0.2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0.2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethyl ether	67/200	ND	5000	Pass
Ethylene oxide	0.2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	<loq< td=""><td>3000</td><td>Pass</td></loq<>	3000	Pass
Methylene chloride	0.2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0.2/0.5	ND	1	Pass

**Heavy Metal Screen** Pass

10/26/2023

Method: MF-CHEM-16

Instrument: Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.05	BLOO	0.5	Pass

Foreign Material Pass

10/26/2023

Method: MF-MACRO-5

Analyte	Findings	Limit	Status	
Sand, Soils, Cinders, and Dirt	ND	25%	Pass	
Mold	ND	25%	Pass	
Imbedded Foreign Material	ND	25%	Pass	
Insect Fragment	ND	1 per 3g	Pass	
Hair	ND	1 per 3g	Pass	
Mammalian Excreta	ND	1 ner 3g	Pass	

**Mycotoxin Screen O** Pass

10/26/2023

MF-CHEM-13 Method:

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/kg)	Findings (µg/kg)	Limit (µg/kg)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/20	ND	20	Pass

10/25/2023 **Water Activity** 

MF 14G051 Method: Instrument: Decagon

Analyte	Findings	Limit	Status
Water Activity	0.44	0.85	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124

Sample #: 1178286 Lot #: CA25HT231012d9I

Page 3 of 4 Report ID: S-2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



(-) = Not Tested, ND = None Detected, <LOQ = Below Limit of Quantitation, LOD = Limit of Detection

All LQC samples were performed and met the acceptance criteria in CCR Title 4 Division 19. Chapter 6. Article 7. §15730. pursuant to §15726.(e)(13).

Reported by



Vu Lam Lab Co Director October 26, 2023



Scan to verify